Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.


1. A four year post for a Postdoctoral Researcher, with Bioinformatics and Immunology interests:
2. A three year post for a Postdoctoral Researcher in Molecular Immunology:

Sarosh Irani

MRC Senior Clinical Fellow | Honorary Consultant Neurologist

  • Head, Oxford Autoimmune Neurology Group
  • MRC Senior Clinical Fellow
  • Honorary Consultant Neurologist
  • Senior Fellow, Oxford BRC
  • Associate Editor @Brain

Autoantibody-mediated neurological diseases

Research Summary

I am a consultant neurologist and clinician-scientist with clinical and laboratory experiences in the field of autoantibody mediated diseases of the nervous system, in particular the central nervous system. I care for patients with these disorders and run a research group to learn more about the origins and treatments of these diseases. I welcome referrals of patients with possible autoimmune neurological conditions.

I have studied the antigenic targets of autoantibodies in patients with encephalitis and epilepsies. In particular, my research has focused on LGI1, CASPR2 and the NMDA-receptor. In addition, I have been involved with projects examining autoantibodies against the GABAA-receptor, glycine receptors and aquaporin-4.

Along with colleagues, I have looked after and met multiple patients with these disorders, phenotypes >150 patients in great detail, and characterised their clinical responses to therapies. These findings have generated, often distinctive, clinical features which correlate well with a high likelihood of an immunotherapy-responsive condition. They have also identified novel clinical descriptions of patients with cognitive, movement and seizure disorders, in particular faciobrachial dystonic seizures - a novel autoimmune epilepsy syndrome which often responds better to immunotherapies than conventional anti-epileptic drugs.

I run a research group combining ~15 talented clinicians, clinician-scientists and basic scientists with the aim of better understanding the causes and potential treatments of this condition. In particular, we study the role of B cell subsets in propagating autoantibody responses. We are funded by the Wellcome Trust, Medical Research Council, British Medical Association, Association of British Neurologists and industry partners.

Key publications

More publications